anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Acute myocardial infarction (AMI) is a common cardiovascular disease worldwide. Circular RNAs (circRNAs) have been shown to exert essential roles in the progression of AMI. However, it remains unclear whether circANKIB1 protects cardiomyocytes from hypoxia-induced injury.
OBJECTIVES: The aim of the study was to elucidate the function and mechanisms of circANKIB1 in AMI.
MATERIAL AND METHODS: The expression of RNA was estimated using a quantitative real-time polymerase chain reaction (qPCR) assay, and the level of protein was determined with the use of western blot analysis. Methyl thiazolyl tetrazolium (MTT) assay was introduced to test cell viability, and a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was used to detect apoptosis. The relative levels of ferrous ion (Fe2+), reactive oxygen species (ROS) and malondialdehyde (MDA) were measured with their corresponding detection kits. The potential target of circANKIB1 and miR-452-5p was predicted using the StarBase database and verified by employing a dual luciferase reporter assay.
RESULTS: This study showed a significant decrease in circANKIB1 in hypoxia-treated H9c2 cells. Hypoxic exposure significantly reduced the viability of H9c2 cells and the expression of GPX4, and increased the content of Fe2+, ROS and MDA. These effects were reversed by the overexpression of circANKIB1. Additionally, miR-452-5p was found to be a direct target of circANKIB1, and the miR-452-5p mimic significantly eliminated the protective effect of circANKIB1 overexpression in hypoxia-induced cells. In addition, miR-452-5p could bind to SLC7A11 and negatively regulate its expression. The knockdown of SLC7A11 abolished the effect of circANKIB1 overexpression on hypoxia-induced cardiomyocyte injury.
CONCLUSIONS: This investigation revealed for the first time that circANKIB1 regulated signaling of the miR-452-5p/SLC7A11 axis, thereby ameliorating hypoxia-induced cardiomyocyte injury. These findings suggest that circANKIB1 might be a useful adjunct in the treatment of AMI.
PURPOSE: A composition containing Lindera plant extract is provided to control ocular tension without side effect. CONSTITUTION: A composition for reducing ocular tension contains 0.1-50 wt% of Lindera plant extract as an active ingredient. The composition is used for preventing or treating glaucoma. The extract is prepared using water, alcohol, or a mixture thereof. The alcohol is C1-C4 alcohol. The composition is a pharmaceutical composition. Lindera includes Lindera erythrocarpa, Lindera obtusiloba, Lindera sericea, and Lindera glauca.
Atherosclerosis of the lower leg arteries is a common disease. Patients with this condition has symptoms of ischemia, for instance intermittent claudication (pain during exercise). Diagnosis of atherosclerosis in the legs is normally done with an interventional x-ray-based angiography (DSA- digital subtraction angiography). This is uncomfortable for the patient, and associated with risks of complications (bleeding, vascular damage, embolism).A novel approach to diagnosing atherosclerosis is the use of magnetic resonance angiography. A variant of this is the whole body magnetic resonance angiography(WB-MRA), that produce a picture of the arteries in almost the whole body (excluding the coronary arteries). WB-MRA has a number of advantages compared to DSA. It does not use ionizing radiation, is not invasive, uses a contrast medium with fewer side affects and finally gives a covers a great deal of the arteries in the body.

This study will compare WB-MRA with DSA in patients with symptoms of peripheral atherosclerosis in the lower legs. We will investigate 2 different contrast agents used for WB-MRA. The patients will be randomized to receive either the contrast medium Dotarem or the contrast medium Vasovist. In both groups we will compare the results of WB-MRA with DSA.
Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
This prospective cohort study aimed to identify characteristics of long COVID and any potential mitigating effects of COVID-19 vaccinations in patients 24 months following COVID-19 infection. Adult patients diagnosed with COVID-19 between February 17, 2020, and March 24, 2020, were scheduled to visit the study hospital four times (6, 12, 18, and 24 months after infection) to assess their symptoms, quality of life, and mental health. Among the 235 patients, 121 (51.5%) completed the study visits. Of these, 59.5% were female, with a median age of 52 years. Mild to moderate disease severity were identified in 101 (83.4%) patients. A total of 75 participants (62.0%) were still experiencing long COVID symptoms 24 months after acute infection. Fatigue, amnesia, difficulty concentrating, and insomnia were the most common symptoms. The frequency of neuropsychiatric symptoms did not differ based on vaccination status or the number of doses received. Quality of life improved over time for the participants, but 32.2% of respondents still reported anxiety/depression at the end of the study. Overall, our cohort demonstrates that long COVID can persist up to 24 months after COVID-19 infection, affecting mental health and quality of life.
Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
Stroke is a major cerebrovascular disease that causing high morbidity, disability and mortality. Management of the acute phase of stroke is critical to functional outcomes. Our study aims to verify an intervention method based on hospital information management decision system for the prevention and management of post-stroke treatment in acute stroke patients and improve long-term functional prognosis.

This study was a multicenter, open-label, parallel, cohort randomized controlled study, recruiting acute ischemic stroke patients with a post-onset National Institutes of Health Stroke Scale (NIHSS) score of ≥ 2 (limb score ≥1) within 7 days from onset of symptoms. This study will recruit a total of 3540 patients in 30 secondary hospitals. Patients in the intervention group will receive the organizational management based clinical decision support system recommended by the guidelines and conduct intervention management for patients with acute ischemic stroke. All patients in control group were treated with conventional diagnosis and treatment. The primary endpoint event was unfavorable functional outcome 3 months after onset. Secondary outcomes were in-hospital complications (including pneumonia, deep vein thrombosis), unfavorable functional outcomes at 6 and 12 months of onset (Modified Rankin Score (mRS) Score 2-5), recurrent stroke at 3, 6, and 12 months, new vascular events (including ischemic stroke, hemorrhagic stroke, myocardial infarction or vascular death) and all-cause death.
NEW MATERIAL:An active substance (IAP) for enhancing secretion of insulin produced by a microorganism of the genus Bordetella. USE:A treating and preventing agent for diabetes, having remarkably weakened leukocytotic action though with an effective pharmacologival activity almost the same as that of IAP. PREPARATION:An active substance (IAP) for enhancing the secretion of insulin produced by a microorganism of the genus Bordetella is reacted with a carbonyl compound of formula I (R1 is H or methyl; R2 is H or 1-3C lower alkyl) or pyridoxal phosphate in the presence of a reducing agent, e.g. sodium boron hydride or a complex of an amine such as pyridine with borane, at 0-40 deg.C in a phosphoric acid buffer solution to introduce a group of formula II or III into the free amino group in IAP and give the aimed IAP derivative. The effective amount thereof for the human body is several tens - several tens of thousands of units/kg expressed in terms of solids. The intravenous administration method is the most effective, and further intraperitoneal, intramuscular administration or direct administration to the interior of the digestive organs, etc. may be cited.
To prevent unwanted cortical activation, Sham TMS will be employed in the Sham TMS group. For the Sham TMS group, a specially designed sham TMS coil will be used for all sham conditions. This sham TMS coil produces auditory signals identical to active TMS coils but is shielded so that actual stimulation does not occur. This approach is currently the state-of-the-art approach to sham TMS procedures and is employed in high-quality clinical TMS trials. Participants in the sham TMS group receive five 20 minute Sham TMS treatment sessions per week for two weeks.
One example aspect of the present disclosure relates to a method for assessing a health of a passenger of an aerial vehicle. The method can include receiving at least one signal indicative of a state of the passenger from one or more sensors of a chair in the aerial vehicle. The method can include determining a health state of the passenger based on the at least one received signal. The method can include determining if the aerial vehicle should land based on the determined health state of the passenger. When a determination is made that the aerial vehicle should land based on the determined health state of the passenger, the method can include identifying a nearest airport. When a determination is made that the aerial vehicle should land based on the determined health state of the passenger, the method can include transmitting a request to land to the identified airport.
PURPOSE:To provide a safe hair tonic composition containing 5-chloro-1H-indazolylacetic acid sodium salt as an active component, and effective to prevent the falling-off of the hair, promote the growth and restoration of hair, and prevent dandruff and itchiness. CONSTITUTION:The objective composition contains 5-chloro-1H-3-indazolyl-acetic acid sodium salt as an active component. The amount of the component to be added to the hair tonic compostion is 0.001-5wt%, preferably 0.05-1.0wt%. The composition may contain a component for conventional hair tonic composition (e.g. ethanol, menthol, glycerol, perfume, dye, etc.) and other hair tonic component (e.g. estrogen, disinfectant, scalp-stimulant, etc.) in addition to the above component. Those components act synergistically with the 5-chloro-1H-3-indazolylacetic acid sodium salt to suppress the falling-off of hair, prevent dandruff and itchiness, and promote the growth and restoration of hair.
BACKGROUND: Falls in older adults are a significant public health concern, and age-related macular degeneration (AMD) and glaucoma have been identified as potential visual risk factors. This study was designed to assess equilibrium function, fall risk, and fall-related self-efficacy (an individual's belief in their capacity to act in ways necessary to reach specific goals) in patients with AMD and glaucoma.
METHODS: This observational study was performed at the Otorhinolaryngology Department of Shinseikai Toyama Hospital. The cohort comprised 60 participants (AMD; n = 30; median age, 76.0 years; and glaucoma; n = 30; median age, 64.5 years). Visual acuity and visual fields were assessed using the decimal best-corrected visual acuity and Humphrey visual field tests, respectively. The evaluation metrics included pathological eye movement analysis, bedside head impulse test, single-leg upright test, eye-tracking test, optokinetic nystagmus, and posturography. Furthermore, we administered questionnaires for fall risk determinants including the Dizziness Handicap Inventory, Activities-Specific Balance Confidence Scale, Falls Efficacy Scale-International, and Hospital Anxiety and Depression Scale. The collected data were analyzed using descriptive statistics, and Spearman's correlation analysis was employed to examine the interrelations among the equilibrium function, fall risk, and other pertinent variables.
RESULTS: Most participants exhibited standard outcomes in equilibrium function evaluations. Visual acuity and field deficits had a minimal impact on subjective dizziness manifestations, degree of disability, and fall-related self-efficacy. Both groups predominantly showed high self-efficacy. No significant correlation was observed between visual acuity or field deficits and body equilibrium function or fall risk. However, greater peripheral visual field impairment was associated with a tendency for sensory reweighting from visual to somatosensory.
CONCLUSION: Self-efficacy was higher and fall risk was relatively lower among patients with mild-to-moderate visual impairment, with a tendency for sensory reweighting from visual to somatosensory in those with greater peripheral visual field impairment. Further studies are required to validate these findings.
In one aspect, the invention provides a method of diagnosis. The diagnostic method may include steps of identifying a patient at risk of an arthritis, the patient having an interferon gamma gene. The patient may be tested to characterize a polymorphism in a first intron of the interferon gamma gene.  The polymorphism may comprise a variable length dinucleotide repeat region within the first intron, and the dinucleotide repeat region may be located at least partly between nucleotides 1349 and 1373 in the interferon, gamma gene. The method may be carried out so as to be capable of identifying alleles such as the 126 by allele and the 122 by allele, as further described herein. The polymorphisms may be distinguished based on a difference in the number of CA repeats in a portion of the first intron of the interferon gamma gene. The invention may also comprise testing a patient for a polymorphism is an HLA protein (or gene), such as the HLA-DRB1 protein.
This is a prospective randomized controlled study where sequential randomization will be applied to patients; The first patient will be included in the 1st group, and the second patient will be included into the 2nd group, and so on. All patients scheduled for hip arthroscopy in our institution during the defined study period are eligible for inclusion. While room temperature irrigation fluids will be used routinely for Group 1, irrigation fluids heated up to 36-38 degrees will be used for the other group. Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer, whose batteries will be changed every two operations. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined.
An example of an information processing system includes a hand-held terminal. The hand-held terminal senses sensor information for determining an emotion of a user. The sensor information may be, for example, information of a sound sensed by a microphone, or information of an image captured by a camera. The information processing system determines the emotion of the user on the basis of the sensor information. The hand-held terminal senses the sensor information in a period during which the hand-held terminal is in a standby state. The standby state is, for example, a state in which a display of the hand-held terminal is turned off.
BACKGROUND: Glycopeptides for ampicillin-susceptible Enterococcus faecalis/faecium bacteremia are readily prescribed depending on the severity of the condition. However, there is limited data on the outcomes of glycopeptide use compared to ampicillin-containing regimens for ampicillin-susceptible E. faecalis/faecium bacteremia. From an antibiotic stewardship perspective, it is important to determine whether the use of glycopeptides is associated with improved clinical outcomes in patients with ampicillin-susceptible E. faecalis/faecium bacteremia.
METHODS: This retrospective cohort study was conducted at a university-affiliated hospital between January 2010 and September 2019. We collected data from patients with positive blood cultures for Enterococcus species isolates. The clinical data of patients who received ampicillin-containing regimens or glycopeptides as definitive therapy for ampicillin-susceptible E. faecalis/faecium bacteremia were reviewed. Multivariate logistic regression analysis was performed to identify risk factors for 28-day mortality.
RESULTS: Ampicillin-susceptible E. faecalis/faecium accounted for 41.2% (557/1,353) of enterococcal bacteremia cases during the study period. A total of 127 patients who received ampicillin-containing regimens (N = 56) or glycopeptides (N = 71) as definitive therapy were included in the analysis. The 28-day mortality rate was higher in patients treated with glycopeptides (19.7%) than in those treated with ampicillin-containing regimens (3.6%) (p = 0.006). However, in the multivariate model, antibiotic choice was not an independent predictor of 28-day mortality (adjusted OR, 3.7; 95% CI, 0.6-23.6).
CONCLUSIONS: Glycopeptide use was not associated with improved mortality in patients with ampicillin-susceptible E. faecalis/faecium bacteremia. This study provides insights to reduce the inappropriate use of glycopeptides in ampicillin-susceptible E. faecalis/faecium bacteremia treatment and promote antimicrobial stewardship.
This study aims to analyze the prevalence of low muscle mass (LMM) and its associated factors among community-dwelling patients with type 2 diabetes (T2D). A retrospective design was employed to analyze the body composition of 2404 adults with T2D aged 18 years and older. LMM was defined as a skeletal muscle index < 7.0 kg/m2 for males and skeletal muscle index < 5.7 kg/m2 for females by bioelectrical impedance analyzer (InBody 770, Korea). Multivariable logistic regression was used to identify the factors related to LMM. The overall prevalence of LMM was 28%. After adjusting for multivariate odds ratios, factors significantly associated with LMM in patients with diabetes include being older than 75 years, female, having a body mass index of <18 kg/m2, and increased percent body fat. We recommend regular LMM evaluations for T2D patients with the previously mentioned characteristics as part of diabetes care.
Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from citrus honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
Overdoses of topiramate have been reported. Signs and symptoms included convulsions, drowsiness, speech disturbance, blurred vision, diplopia, impaired mentation, lethargy, abnormal coordination, stupor, hypotension, abdominal pain, agitation, dizziness and depression. The clinical consequences were not severe in most cases, but deaths have been reported after overdoses involving topiramate. 

Topiramate overdose has resulted in severe metabolic acidosis [see Warnings and Precautions ( 5.4)] . 

A patient who ingested a dose of topiramate between 96 and 110 g was admitted to a hospital with a coma lasting 20 to 24 hours followed by full recovery after 3 to 4 days. 

In acute topiramate overdose, if the ingestion is recent, the stomach should be emptied immediately by lavage or by induction of emesis. Activated charcoal has been shown to adsorb topiramate in vitro. Hemodialysis is an effective means of removing topiramate from the body.
Objective: To examine the impact of moderate alcohol consumption on the progression of chronic kidney disease (CKD) in individuals diagnosed with non-alcoholic fatty liver disease (NAFLD), as NAFLD has been identified as an autonomous risk factor for CKD and previous research has demonstrated a reduction in overall mortality in NAFLD patients who consume alcohol in moderation.Methods: This study included participants from ten consecutive rounds of the National Health and Nutrition Examination Survey (NHANES:1998-2018). Multivariate logistic regression models were employed to assess the impact of moderate alcohol consumption on chronic kidney disease (CKD) in both male and female populations. Subgroup analysis was conducted by categorizing patients with non-alcoholic fatty liver disease (NAFLD) based on the Fibrosis-4 (FIB-4) index.Results: 17040 participants were eligible to be included in the study. The logistic regression analysis model showed that moderate alcohol consumption was a protective factor for CKD in male NAFLD patients, with an unadjusted OR: 0.37 (0.22,0.65), and p < 0.001. After further adjustment, the association persisted. However, the association was not significant in female patients with NAFLD. Among men with low risk of liver fibrosis group, moderate alcohol consumption remained a protective factor for CKD (OR = 0.32, 95% CI 0.12-0.84, p = 0.02), but the association was not significant in the high risk of liver fibrosis group. In female patients, both moderate alcohol consumption and excessive alcohol consumption were not significantly associated with CKD in either the low-risk group or the high-risk group.Conclusion: Moderate alcohol consumption is associated with a lower prevalence of CKD in men with NAFLD.
Full-term infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
A method for collecting a life log generated from a wearable device or a personal health measurement device performs a step of collecting life log data from a server of a wearable device after being authenticated by a user, a step of collecting data transmitted from a mobile terminal connected wirelessly with a personal health measurement device equipped with Bluetooth or Wifi through respective collection units. The life log data collected through the collection units are collected in the respective data formats for the same kind of data and for each providing manufacturer server. The collected data have different units of measure, terms, data types and structures. A life log integration unit receives the life log from the collection unit and converts the structure of the life log according to a life log common model schema. The life log common model schema has terms and a semantic mapping relation between each data structure and a common model. The life log applied with the common data model is stored in life log integration DB. The stored life log integration DB is authenticated by a life log owner when requested by an external personal health care service server, and then transmitted to the server through a life log transmission unit.